Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico.
Ponce-de-León S, Torres M, Soto-Ramírez LE, Calva JJ, Santillán-Doherty P, Carranza-Salazar DE, Carreño JM, Carranza C, Juárez E, Carreto-Binaghi LE, Ramírez-Martínez L, Paz De la Rosa G, Vigueras-Moreno R, Ortiz-Stern A, López-Vidal Y, Macías AE, Torres-Flores J, Rojas-Martínez O, Suárez-Martínez A, Peralta-Sánchez G, Kawabata H, González-Domínguez I, Martínez-Guevara JL, Sun W, Sarfati-Mizrahi D, Soto-Priante E, Chagoya-Cortés HE, López-Macías C, Castro-Peralta F, Palese P, García-Sastre A, Krammer F, Lozano-Dubernard B. Ponce-de-León S, et al. Among authors: santillan doherty p. NPJ Vaccines. 2023 May 10;8(1):67. doi: 10.1038/s41541-023-00662-6. NPJ Vaccines. 2023. PMID: 37164959 Free PMC article.
On clinical research and the pharmaceutical industry.
Santillán-Doherty P, Pérez-Padilla R. Santillán-Doherty P, et al. Gac Med Mex. 2023;159(4):354-355. doi: 10.24875/GMM.M23000790. Gac Med Mex. 2023. PMID: 37699211 Free article. English. No abstract available.
Mutation profile in liquid biopsy tested by next generation sequencing in Mexican patients with non-small cell lung carcinoma and its impact on survival.
Martínez-Herrera JF, Sánchez Domínguez G, Juárez-Vignon Whaley JJ, Carrasco-Cara Chards S, López Vrátný C, Guzmán Casta J, Riera Sala RF, Alatorre-Alexander JA, Seidman Sorsby A, Cruz Zermeño M, Conde Flores E, Flores-Mariñelarena RR, Sánchez-Ríos CP, Martínez-Barrera LM, Gerson-Cwilich R, Santillán-Doherty P, Jiménez López JC, López Hernández W, Rodríguez-Cid JR. Martínez-Herrera JF, et al. Among authors: santillan doherty p. J Thorac Dis. 2024 Jan 30;16(1):161-174. doi: 10.21037/jtd-23-1029. Epub 2024 Jan 17. J Thorac Dis. 2024. PMID: 38410597 Free PMC article.
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.
Rodriguez-Cid JR, Juarez-Vignon Whaley JJ, Sánchez-Domínguez G, Guzmán-Casta J, Carrasco-CaraChards S, Guzmán-Huesca J, Riera-Sala R, Sánchez-Ríos CP, Cruz-Zermeño M, Seidman-Sorsby A, de Jesús Rodríguez-Zea I, Alatorre-Alexander JA, Martínez-Barrera LM, Santillán-Doherty PJ, Godina-Flores A, Imaz-Olguin V, Sosa-Sánchez R, Green-Renner D. Rodriguez-Cid JR, et al. Among authors: santillan doherty pj. J Cancer Res Clin Oncol. 2023 Aug;149(9):5479-5491. doi: 10.1007/s00432-022-04454-8. Epub 2022 Dec 4. J Cancer Res Clin Oncol. 2023. PMID: 36463530
Survival prognostic factors in unresectable/advanced primary thoracic sarcomas.
Rodriguez-Cid JR, Juarez-Vignon Whaley JJ, Sánchez-Domínguez G, Guzmán-Casta J, Carrasco-CaraChards S, Alatorre-Alexander JA, Martínez-Barrera LM, Sánchez-Rios CP, Flores-Mariñelarena RR, Seidman-Sorsby A, Cruz-Zermeño M, Rodríguez-Zea IJ, Santillan-Doherty PJ. Rodriguez-Cid JR, et al. Among authors: santillan doherty pj. J Thorac Dis. 2022 Sep;14(9):3376-3385. doi: 10.21037/jtd-22-472. J Thorac Dis. 2022. PMID: 36245612 Free PMC article.
Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico.
Ponce-de-León S, Torres M, Soto-Ramírez LE, Calva JJ, Santillán-Doherty P, Carranza-Salazar DE, Carreño JM, Carranza C, Juárez E, Carreto-Binaghi LE, Ramírez-Martínez L, Paz-De la Rosa G, Vigueras-Moreno R, Ortiz-Stern A, López-Vidal Y, Macías AE, Torres-Flores J, Rojas-Martínez O, Suárez-Martínez A, Peralta-Sánchez G, Kawabata H, González-Domínguez I, Martínez-Guevara JL, Sun W, Sarfati-Mizrahi D, Soto-Priante E, Chagoya-Cortés HE, López-Macías C, Castro-Peralta F, Palese P, García-Sastre A, Krammer F, Lozano-Dubernard B. Ponce-de-León S, et al. Among authors: santillan doherty p. medRxiv [Preprint]. 2022 Feb 9:2022.02.08.22270676. doi: 10.1101/2022.02.08.22270676. medRxiv. 2022. PMID: 35169806 Free PMC article. Preprint.
A comparative study of immunotherapy as second-line treatment and beyond in patients with advanced non-small-cell lung carcinoma.
Rodríguez-Cid JR, Chards SC, González-Espinoza IR, García-Montes V, Garibay-Díaz JC, Hernández-Flores O, Riera-Sala R, Gozalishvili-Boncheva A, Alatorre-Alexander JA, Martínez-Barrera LM, Sánchez-Ríos CP, Martinez-Camacho A, Martínez-Herrera JF, Guzmán-Casta J, Flores-Mariñelarena RR, Diaz-Rico J, Santillán-Doherty P. Rodríguez-Cid JR, et al. Among authors: santillan doherty p. Lung Cancer Manag. 2021 Mar 11;10(3):LMT47. doi: 10.2217/lmt-2020-0027. eCollection 2021 Sep. Lung Cancer Manag. 2021. PMID: 34408789 Free PMC article.
92 results